Highly regulated, with strict compliance rules, work can be in-house or in collaboration with another entity. Guidance includes practice notes on UK and EU regime for clinical trials and various precedents.
Patents and supplementary protection certificates are significant to many life sciences businesses. We have practice notes on pharmaceutical patents, biotechnology patents, IP protection for medical devices and more.
This content includes guidance on marketing authorisations, orphan and paediatric medicines, pharmacovigilance, manufacturing, unlicensed and off-label medicines.
Covering key areas of medical devices regulation including classification, conformity assessments, clinical and performance evaluation as well as post-market surveillance.
The European Medicines Agency (EMA) has published guidance on submitting electronic product information (ePI) for centrally authorised medicines...
The Medicines and Healthcare products Regulatory Agency (MHRA) has published the National Commission into the Regulation of AI in Healthcare’s...
This week's edition of Life Sciences weekly highlights includes an analysis of the request for a preliminary ruling in Case C-371/26 in the context of...
The Medical Device Coordination Group (MDCG) has published an updated version of its guidance on the classification of in vitro diagnostic medical...
The Department of Health and Social Care (DHSC) has published impact assessments for Health Bill measures that would give the Medicines and Healthcare...
FORTHCOMING CHANGE: it was announced at Budget 2025 that the government will legislate in Finance Bill 2026–27 to ‘clarify’ the tax treatment of image...
Boilerplate provisions in public sector contractsThis Practice Note looks at payment of subcontractor clauses in public sector contracts. For more...
This Practice Note sets out the law on the use of boilerplate provisions in business-to-consumer (B2C) contracts. As well as providing details on the...
This Practice Note is intended to be used for horizon scanning purposes to track the progress of key UK regulatory and legal developments in relation...
No medicinal product may be placed on the market without having first obtained an approval known as a marketing authorisation (MA). The MA sets out...
Strictly private and confidentialTo: [insert buyer name][insert buyer address]Date: [insert date]Dear [insert buyer contact name],Proposed acquisition...
This Agreement is made on [date]Parties1[Insert name of party][ of [insert details] OR a company incorporated in [England and Wales] under number...
Every director of a company owes a number of duties to the company they are appointed to. Many of those duties have been developed by the courts over...
1Definitions and interpretation1.1In this Agreement:[Insert each definition bespoke to the Agreement]1.2In this Agreement:1.2.1a reference to this...
1Definitions and interpretation1.1In this Agreement:Affiliate•means any entity that directly or indirectly Controls, is Controlled by or is under...
Introduction to technology transfer agreements in the Life Sciences industryWhat is a technology transfer agreement?The term ‘technology transfer...
Regulation of cosmetic products in the UKThis Practice Note provides an overview of the UK regulatory framework for cosmetics. It sets out the legal...
Intellectual property protection for medical devicesChanges to intellectual property (IP) law from 1 January 2021Before discussing how intellectual...
Second and subsequent medical use patent claimsBackground to medical use claimsSecond (and subsequent) medical use patent claims are specific to the...
The experimental use and Bolar-type exemptions to patent infringementPatent systems are intended to foster innovation, not to impede it. For this...
The PMCPA has recently launched a consultation to update:•the 2021 ABPI Code of Practice•the Constitution and Procedure which sets out how the PMCPA...
Clinical Research Organisation (CRO) master services agreementDATA PROTECTION NOTICE: Please note that the drafting of clause 7 (Data Protection), in...
The EU Clinical Trials RegulationThis Practice Note looks at Regulation (EU) 536/2014, the EU Clinical Trials Regulation (CTR), which governs clinical...
Medical devices due diligence questionnaireIntroductionThis medical devices regulatory due diligence questionnaire relates to the proposed purchase by...
Biotechnology patentsPatenting biotechnological inventionsBiotechnological inventions are, in principle, patentable. While there is no general...
Unlicensed medicinal products and off-label use of medicinal productsThis Practice Note explores unlicensed medicinal products and the various ways...
The Medicines and Healthcare products Regulatory Agency (MHRA) has released guidance on the implementation of changes to pharmacovigilance for...
The regulation of medical devices in the UKThis Practice Note provides an overview of the UK regulatory regime for medical devices. It explains the...
The National Archives has published the judgment in British Standards Institution v RRR Manufacturing Pty Ltd, R (on the application of) [2024] EWCA...
The Competition and Markets Authority (CMA) has announced a Phase 1 merger inquiry into Roche Diagnostics Ltd's acquisition of point-of-care testing...
The Department for Science, Innovation and Technology (DSIT) has released the interim International Scientific Report on the Safety of Advanced...
The regulation of advanced therapy medicinal productsThe development of medicine, biomicrobiology and biotechnology has led to the emergence of a...
A medicinal product which contains the same active substances and has the same pharmaceutical form as the original branded reference medicinal product, and whose bioequivalence with the reference medicinal product has been demonstrated by appropriate bioavailability studies, as defined in Article 10(2)(b) of Directive 2001/83/EC.
Any substance or combination - presented as having properties for treating or preventing disease in humans; or - which may be administered to humans either with a view to restoring, correcting or modifying physiological functions by exerting a pharmacological, immunological or metabolic action, or to making a medical diagnosis.
The science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other medicine-related problem.